In part 7/10 of 'Liver Insights: Illuminating the Path Through MASLD & MASH', we are thrilled to have as our guest, Dr. Naim Alkhouri, MD, FAASLD, Chief Medical Officer (CMO), Director of the Steatotic Liver Program, at Arizona Liver Health. This segment is 'Treatment Options and…

Whether it's accessing standard care for liver disease, participating in clinical research, or preventing hepatitis and STIs, everyone deserves quality healthcare. Let's advocate for 'My health, my right' worldwide.

#WorldHealthDay #MyHealthMyRight #azliver

Big thanks to all at The World Vaccine Congress for an amazing week! To those we've met, let's keep the momentum! And to those we haven't, reach out to Michelle Jones ([email protected]) to schedule a meet.

Big News in Liver Health:  Rezdiffra™ (resmetirom) Approved for NASH/MASH, targeting liver fibrosis and high cholesterol.

Join us in advancing liver care. For more details and referrals, visit bit.ly/rezdiffra.

#NASH #MASH #LiverHealth # Rezdiffra #PatientCare

New FDA-Approved Rezdiffra™ (resmetirom): Your Questions Answered!

Click here to learn more about Rezdiffra and if it may be right for your patients! bit.ly/rezdiffra

#Rezdiffra #NASH

Excited to be at the World Vaccine Congress this year! Let's collaborate for impactful research! We offer diverse participant populations, rapid trial initiation, state-of-the-art facilities, and experienced investigators #ClinicalTrials #ResearchPartnership

Exciting news in #LiverDisease treatment! Rezdiffra™ (resmetirom) is a new drug targeting NASH, now called MASH, by focusing on thyroid hormone receptor-beta to improve liver health. It's showing promise in reducing inflammation, fibrosis & bad lipids. Huge leap forward!

Exciting news in #LiverDisease treatment! Rezdiffra™ (resmetirom) is a new drug targeting NASH, now called MASH, by focusing on thyroid hormone receptor-beta to improve liver health. It's showing promise in reducing inflammation, fibrosis & bad lipids.

Attending the Philippines Digestive Health Week in Manila was truly an enriching experience. The event was impeccably organized, and I am grateful for the opportunity to present and engage with such a dynamic community Naim Alkhouri Department of Health Philippines Anita Kohli Ann Moore Michelle Jones

The FDA has approved Rezdiffra (resmetirom), a groundbreaking treatment for NASH/MASH with liver fibrosis. This new oral medication, targeting thyroid hormone receptor beta, marks a significant advancement in liver disease therapy. Naim Alkhouri Anita Kohli Madrigal Pharmaceuticals

The Philippine Digestive Health Week – Joint Annual Convention (PDHW-JAC) 2024, is just around the corner! We're thrilled to announce that our very own Dr. Naim Alkhouri will be among the esteemed speakers, sharing invaluable insights in the field of Hepatology.

The Philippine Digestive Health Week – Joint Annual Convention (PDHW-JAC) 2024, is just around the corner! We're thrilled to announce that our very own Dr. Naim Alkhouri will be among the esteemed speakers, sharing invaluable insights in the field of Hepatology.

Wishing everyone a joyful International Women's Day! Supporting and empowering women enriches us all, each day and always.

On this special occasion, we take pride in our team, where 78% are remarkable women who contribute immensely to our success.

#IWD

Arizona Liver Health and the Desert Liver Conference would like to thank all its attendees, sponsors, partners and leading industry speakers. The dedication, expertise, and active participation have truly made a difference in advancing liver care.

Naim Alkhouri Anita Kohli

Don't miss out on the Desert Liver Conference on March 1 & 2! Register now to guarantee your spot for two days packed with cutting-edge scientific programs and a chance to connect with peers passionate about advancing liver disease care.

Earn 10.25 CME/ABIM MOC credits!

Excitement is in the air as the weekend approaches, and we're thrilled to bring you an exciting product theater courtesy of Madrigal Pharmaceuticals. This session promises valuable insights and cutting-edge advancements in MASH (metabolic dysfunction-associated steatohepatitis).

Exciting news! Our newest Flagstaff office is officially open for business! Now, under one roof, you'll find the dedicated teams of Arizona Liver Health, Arizona Clinical Trials, and VEN Centers.

We can't wait to welcome you to our new space!

#ALH #ACT #VEN #Flagstaff

Join us at the Doing it in the Desert: Viral Hepatitis and STI Elimination Summit on March 1 at the Arizona Biltmore!
For a limited time, early bird registration allows attendees to register at no cost. Sign up today!

vencenters.com/sti-eliminatio…

Don't miss out on the Desert Liver Conference on March 1 & 2! Register now to guarantee your spot for two days packed with cutting-edge scientific programs and a chance to connect with peers passionate about advancing liver disease care. See you there!

desertliver.com

It's Phlebotomists Recognition Week! A huge shoutout to our phlebotomists in our clinics and research department—thank you for your dedication to our patients and advancing medical research!

#PhlebotomistsWeek #azliver #azclinicaltrials #crioh